Skip to content

Asarina Pharma AB (publ) releases Annual Report 2022

(Stockholm, 28 April 2023) Asarina Pharma’s 2022 Annual Report contains analysis and insights into its recent positive Phase IIa results for Tourette syndrome, as well as 2022 financial statements and outlook. Additional content includes investor FAQs with CEO Peter Nordkild and clinical insights from Clinical Neurologist Dr Heidi Biernat (Head of the Tourette Clinic at Bispebjerg University Hospital) on today’s Tourette treatment landscape and patients’ experience of Sepranolone.

The full Annual Report 2022 is available on:

Research and Development: This year, Asarina’s Annual Report includes extra content for shareholders and investors on the company’s Phase IIa results for Tourette syndrome. This includes:

  • An extended CEO Statement covering scientific validation, four key takeaways and the company’s current activities around Business Development and a future Phase IIb study.
  • An Investor FAQ with Asarina’s CEO which looks at the competitive landscape for Tourette plus the implications of the study’s consistently positive secondary clinical endpoint results.
  • Clinical insights from Clinical Neurologist Dr Heidi Biernat on today’s treatments for Tourette including antipsychotics and CBIT, plus her observations of Sepranolone in- clinic.

Financial results and outlook: throughout 2022, Asarina continued its strict cost-management approach, ensuring cash for the completion of its Phase IIa study. External R&D costs fell to SEK 7.3 million from SEK 29.9 million in 2021. The Group had a net cash outflow of SEK 8.8 million in 2022 compared with SEK 36.8 million in 2021, due to the reduction in R&D and staff costs. At the end of 2022, the Group had total cash of SEK 13.6 million.

The positive results from Asarina’s Phase IIa study in Tourette Syndrome, in a condition that has long had an unmet need for a safer, more tolerable 1st line pharmaceutical treatment, are creating industry interest. Asarina is presently pursuing dialogues with prospective partners within CNS and neurology in particular while at the same time exploring the possibilities for funding of a Phase IIb study. The company has sufficient funds to continue these activities up to at least the end of 2023.

Read the full CEO Statement here: